Botox maker Allergan will technically buy its bigger US rival in a deal designed to avoid US taxes
Medecins Sans Frontieres wants GlaxoSmithKline and Pfizer to reduce cost of pneumococcal vaccines
AstraZeneca claims £55-per-share bid undervalues the company and carries a 'big execution risk'
Oil giant is hoping to draw a line under Deepwater Horizon disaster by paying fine, but civil lawsuits are bound to follow
Pharmaceutical giant vows to build its first new facility in Britain for 40 years